Rajesh Dhairyawan, MD
Cardiovascular Disease · Miami, FLNPI 1497758692
Payments from drug & device makers
Across 227 payments — averaging $38.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$2K
- Abbott$1K
- Amgen$992
- Novartis$703
- E.r. Squibb & Sons, L.L.C.$617
- ZOLL Circulation Inc$578
- plus $3K from 23 others
What the payments were for
- Food & beverage$8,623100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 14 | $1,516 |
| Abbott | 21 | $1,209 |
| Amgen | 47 | $992 |
| Novartis | 25 | $703 |
| E.r. Squibb & Sons, L.L.C. | 27 | $617 |
| ZOLL Circulation Inc | 7 | $578 |
| Boston Scientific | 7 | $410 |
| Medtronic(2 entities) | 3 | $325 |
| Kestra Medical Technology Services, Inc. | 7 | $284 |
| Amarin Pharma, Inc. | 13 | $268 |
| AstraZeneca | 13 | $232 |
| Impulse Dynamics (USA) Inc. | 4 | $226 |
| Pfizer | 9 | $191 |
| Lexicon Pharmaceuticals, Inc. | 4 | $184 |
| Atricure, Inc. | 2 | $153 |
| Heartflow, Inc. | 1 | $148 |
| Shockwave Medical, Inc | 1 | $147 |
| Johnson & Johnson | 7 | $123 |
| Bayer | 2 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $55 |
| Kowa Pharmaceuticals America, Inc. | 2 | $51 |
| Terumo Medical Corporation | 1 | $30 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| GSK | 1 | $22 |
| Philips North America LLC | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Medicure Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solia$901
- Rivacor$901
- Edora$901
- BioMonitor$901
- Acticor$901
- Catheter$426
- OPTIMIZER$305
- TherOx DS2 Console$288
- Downstream Cartridge$288
- Repatha$244
- ENTRESTO$240
- Mosaic$193
- Assurity Pacemaker$165
- FFRct$148
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$147
- GALLANT$140
- Temperature Management System$139
- Temperature Management System Start-Up Kit$139
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$126
- Confirm Rx$123
How this compares
$8,644 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 131 | $173,171 |
| EliquisApixaban | 149 | $164,844 |
| Repatha SureclickEvolocumab | 65 | $56,802 |
| XareltoRivaroxaban | 43 | $48,412 |
| BrilintaTicagrelor | 44 | $30,735 |
| FarxigaDapagliflozin Propanediol | 21 | $23,738 |
| LivaloPitavastatin Calcium | 23 | $16,298 |
| Praluent PenAlirocumab | 12 | $8,205 |
| VascepaIcosapent Ethyl | 14 | $6,530 |
| Metoprolol Succinate | 186 | $2,424 |
| Atorvastatin Calcium | 214 | $1,842 |
| Nifedipine ErNifedipine | 70 | $1,669 |
| Bumetanide | 19 | $1,495 |
| Ezetimibe | 47 | $1,149 |
| Bisoprolol Fumarate | 38 | $1,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $703 | $173,171131 claims |
| PfizerEliquis | $191 | $164,844149 claims |
| AstraZenecaBrilinta, Farxiga | $232 | $54,47365 claims |
| Johnson & JohnsonXarelto | $123 | $48,41243 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $51 | $16,29823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Miami
- Jonathan FialkowMiami$2.6M
- Melvin Martinez-CastrillonMiami$1.6M
- Theodore FeldmanMiami$637K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.